Finerenone Reduces New-Onset Atrial Fibrillation Across the Spectrum of Cardio-Kidney-Metabolic Syndrome: The FINE-HEART Pooled Analysis.

In the FINE-HEART pooled analysis of more than 14,500 trial participants, the nonsteroidal mineralocorticoid receptor antagonist finerenone reduced the risk of new-onset atrial fibrillation or flutter by 17%, with consistent benefit across the cardio-kidney-metabolic spectrum.